Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Veloxis Pharmaceuticals publishes Annual Report 2012


      News provided by

      Veloxis Pharmaceuticals A/S

      Mar 06, 2013, 08:23 ET

      Share this article

      Share this article


      HORSHOLM, Denmark, March 6, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2012. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

      This company announcement should be read in conjunction with Veloxis' annual report 2012 published separately today.

      Full Year 2012 Highlights

      • Enrollment completed in the pivotal LCP-Tacro™ Phase III study in de novo kidney transplant patients.
      • Restructuring of the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-Tacro™.  Other pipeline activities will be discontinued, including early phase research activities.
      • Exclusive distribution agreement with Chiesi Farmaceutici S.p.A. for the commercialization and distribution of its novel formulation immunosuppressant drug candidate LCP-Tacro™ in certain countries, including Europe, Turkey and CIS countries (Russia and former USSR republics). Under the terms of the agreement, Veloxis will receive up-front and milestone payments of up to USD 47.5 million (in aggregate). The milestone payments are subject to the achievement of certain regulatory milestones and sales targets.
      • Fully subscribed rights issue of 1,206,779,946 offer shares with a nominal value of DKK 0.10 each at DKK 0.35 per share has been completed. The net proceeds from the rights issue is DKK 409 million.
      • Results of a preliminary analysis from the first 16 patients in its Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) clinical trial. Results from the first 16 patients demonstrated a trend toward a reduction in tremor following the switch from twice-daily tacrolimus to once-daily LCP-Tacro™.
      • During 2012, Veloxis recognized DKK 6.9 million in revenue compared to no revenue in 2011. Revenue in 2012 consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A.
      • Research and development costs decreased by DKK 11.3 million, or by 5.1%, from DKK 222.0 million in 2011 to DKK 210.7 million in 2012. Research and development costs are mainly attributable to the ongoing phase III trial in LCP-Tacro™ (de novo patients, Study 3002).
      • Administrative expenses decreased by DKK 10.9 million or by 22.9%, from DKK 47.8 million in 2011 to DKK 36.9 million in 2012. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the reduction in the number of employees that took place in May 2012.
      • Restructuring cost includes salary payments to former employees in connection with the reduction in headcount in May 2012 and a write-down of laboratory equipment and laboratory improvements due to the discontinuation of pipeline activities not related to LCP-Tacro™.
      • During 2012, Veloxis recognized DKK 262.7 million in net loss compared to DKK 252.6 million in 2011. The net loss is in line with management's expectations for 2012 as reported on 22 August 2012 in connection with the second quarter interim report, which projected a net loss of DKK 240 - 270 million.
      • As per 31 December 2012, the balance sheet reflects cash and cash equivalents of DKK 496.8 million compared to DKK 297.7 million as per 31 December 2011. The increase in cash position reflects the total net proceeds from the offering of DKK 409 million, partially offset by expenditures associated with the operating activities in 2012. The cash position is in line with management's expectations for 2012, which projected a cash position at the end of 2012 of DKK 490 - 530 million.

      Conference Call

      On 6 March, 2013, Veloxis' Management will host a conference call, at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM ET (New York), 5:00 AM PT (San Francisco).

      To access the live conference call, please dial one of the following numbers:
      +45 32 72 80 18 Denmark
      +44 (0) 1452 555 131 UK
      +1 866 682 8490 USA
      Access code 13759590

      Following the conference call, a recording will be available on the company's website www.veloxis.com. A presentation will be available on Veloxis' website (under 'Investors') one hour prior to the scheduled time of the conference call.


      Financial Highlights













      DKK'000

      2012

      2011

      2010

      2009

      2008








      Income Statement






      Revenue

      6,868

      -

      1,496

      2,476

      170,122

      Research and development costs

      (210,739)

      (222,053)

      (210,426)

      (210,140)

      (270,875)

      Administrative expenses

      (36,889)

      (47,814)

      (52,198)

      (62,381)

      (73,311)

      Operating loss before restructuring cost

      (240,760)

      (269,867)

      (261,128)

      (270,045)

      (174,064)

      Restructuring cost

      (21,462)

      -

      (10,894)

      (9,489)

      -

      Operating loss

      (262,222)

      (269,867)

      (272,022)

      (279,534)

      (174,064)

      Net financial income / (expenses)

      (850)

      16,048

      (759)

      8,540

      24,285

      Loss before tax

      (263,072)

      (253,819)

      (272,781)

      (270,994)

      (149,779)

      Tax for the period

      363

      1,193

      (1,425)

      -

      -

      Net loss for the period

      (262,709)

      (252,626)

      (274,206)

      (270,994)

      (149,779)








      Balance Sheet






      Cash and cash equivalents

      496,834

      297,727

      531,519

      333,429

      600,130

      Total assets

      509,271

      320,927

      562,906

      379,269

      646,293

      Share capital

      165,932

      452,543

      452,543

      56,568

      56,288

      Total equity

      409,737

      255,900

      498,238

      317,281

      572,323

      Investment in property, plant and equipment

      260

      2,981

      2,583

      11,043

      6,571








      Cash Flow Statement






      Cash flow from operating activities

      (205,870)

      (234,637)

      (238,148)

      (251,158)

      (102,560)

      Cash flow from investing activities

      169,712

      (169,778)

      (2,658)

      (11,011)

      (6,628)

      Cash flow from financing activities

      404,304

      (5,948)

      440,014

      729

      373,637

      Cash and cash equivalents at period end

      496,834

      297,727

      531,519

      333,429

      600,130








      Financial Ratios






      Basic and diluted EPS (DKK)

      (0.43)

      (0.56)

      (2.84)

      (4.80)

      (3.06)

      Weighted average number of shares

      607,511,489

      452,542,480

      96,707,708

      56,443,701

      49,006,500

      Average number of employees (FTEs)

      48

      52

      59

      93

      102

      Assets/equity

      1.24

      1.25

      1.13

      1.20

      1.13

      Fourth Quarter 2012 Highlights

      • Research and development cost were realized at DKK 41.9 million compared to DKK 61.8 million in same period in  2011, and DKK 49.4 million in the previous quarter.
      • Administrative expenses were realized at DKK 10.2 million compared to DKK 11.4 million in same period in 2011, and DKK 7.0 million in the previous quarter.
      • Operating loss amounted to DKK 45.3 million, while net loss was realized at DKK 46.5 million.

      Financial Highlights









      Quarterly Numbers in DKK




















      Q4

      Q3

      Q2

      Q1

      Q4

      Q3

      Q2

      Q1



      2012

      2012

      2012

      2012

      2011

      2011

      2011

      2011



      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000











      Income Statement









      Revenue

      6,868

      -

      -

      -

      -

      -

      -

      -

      Research and development costs

      (41,890)

      (49,362)

      (56,639)

      (62,848)

      (61,763)

      (43,079)

      (64,951)

      (52,261)

      Administrative expenses

      (10,235)

      (6,961)

      (9,462)

      (10,231)

      (11,385)

      (12,568)

      (12,137)

      (11,724)

      Operating loss before restructuring cost

      (45,257)

      (56,323)

      (66,101)

      (73,079)

      (73,148)

      (55,647)

      (77,088)

      (63,985)

      Restructuring cost

      -

      -

      (21,462)

      -

      -

      -

      -

      -

      Operating loss

      (45,257)

      (56,323)

      (87,563)

      (73,079)

      (73,148)

      (55,647)

      (77,088)

      (63,985)

      Net financial income / (expenses)

      (2,302)

      993

      2,051

      (1,592)

      4,528

      11,363

      2,008

      (1,850)

      Loss before tax

      (47,559)

      (55,330)

      (85,512)

      (74,671)

      (68,620)

      (44,284)

      (75,080)

      (65,835)

      Tax for the period

      1,034

      (223)

      (130)

      (318)

      373

      1,120

      (300)

      -

      Net loss for the period

      (46,525)

      (55,553)

      (85,642)

      (74,989)

      (68,247)

      (43,164)

      (75,380)

      (65,835)











      Balance Sheet









      Cash and cash equivalents

      496,834

      86,683

      152,720

      213,786

      297,727

      348,252

      402,213

      462,319

      Total assets

      509,271

      99,590

      167,799

      235,187

      320,927

      370,865

      426,860

      490,578

      Share capital

      165,932

      45,254

      45,254

      452,543

      452,543

      452,543

      452,543

      452,543

      Total equity

      409,737

      42,103

      98,968

      182,545

      255,900

      322,516

      363,606

      436,200

      Investment in property,









      plant and equipment

      43

      -

      126

      91

      1,123

      602

      635

      621











      Cash Flow Statement









      Cash flow from operating activities

      (399)

      (62,707)

      (62,400)

      (80,364)

      (52,139)

      (60,481)

      (56,621)

      (65,396)

      Cash flow from investing activities

      56,619

      59,486

      24,174

      29,433

      26,101

      25,878

      77,845

      (299,602)

      Cash flow from financing activities

      410,149

      (3,450)

      (1,085)

      (1,310)

      (1,670)

      (1,445)

      (1,426)

      (1,407)

      Cash and cash equivalents









      at period end

      496,834

      86,683

      152,720

      213,786

      297,727

      348,252

      402,213

      462,319











      Financial Ratios









      Basic and diluted EPS

      (0.08)

      (0.12)

      (0.19)

      (0.17)

      (0.15)

      (0.10)

      (0.17)

      (0.15)

      Weighted average number of shares

      607,511,489

      452,542,480

      452,542,480

      452,542,480

      452,542,480

      452,542,480

      452,542,480

      452,542,480

      Average number of employees (FTEs)

      33

      49

      55

      55

      51

      51

      52

      54

      Assets/equity

      1.24

      2.37

      1.70

      1.29

      1.25

      1.15

      1.17

      1.12











      The quarterly numbers have not been audited.







      Outlook for 2013

      Veloxis is expecting an operating loss of DKK 170 - 200 million compared to the realized operating loss of DKK 262 million in 2012. The net loss is likewise expected to be in the range of DKK 170 - 200 million compared to the net loss of DKK 263 million in 2012. As of 31 December 2012, the Company's cash position equaled DKK 497 million and the Company's 31 December 2013 cash position is expected to be in the range of DKK 270 - 310 million.

      The above estimates are subject to possible changes primarily due to the timing and variation of clinical activities, related costs, royalty and other partner income, and fluctuating exchange rates.

      Important events following the balance sheet date
      Following the balance sheet date no material events have occurred.

      For more information, please contact:




      Veloxis Pharmaceuticals A/S




      John D. Weinberg

      Johnny Stilou

      Executive Vice President & CCO

      Executive Vice President & CFO

      Mobile: +1 732 321 3208

      Phone: + 45 21 227 227

      Email: [email protected]

      Email: [email protected]

      About LCP-Tacro™ and tacrolimus
      Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. LCP-Tacro™ is an investigational drug that is being developed as a once-daily tablet version of tacrolimus, with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

      About Veloxis Pharmaceuticals
      Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is LCP‐Tacro™ for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low‐scale up costs.  Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

      For further information, please visit www.veloxis.com.

      SOURCE Veloxis Pharmaceuticals A/S

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.